In sarcomas, breast cancer and colorectal cancer, GBP2 shapes the immune microenvironment, and an elevated GBP2 expression is related to a favorable response to anti-PD1 therapy and to tumor-infiltrating T cells. Here, GBP2 is linked to neoplasm.